Infographic of: Phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients with DLL3-positive tumours: focus on extrapulmonary neuroendocrine carcinomas

Gambardella, Valentina; Capdevila, Jaume; Kuboki, Yasutoshi; B Alese, Olatunji; Morgensztern, Daniel; Sayehli, Cyrus; F Sanmamed, Miguel; Arriola, Edurne; Oum’ Hamed, Zohra; Song, Eric; Studeny, Matus

doi:10.60915/Boehringer-figshare.27959802.v1

Infographic of: Phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients with DLL3-positive tumours: focus on extrapulmonary neuroendocrine carcinomas

poster

posted on 2024-12-04, 11:05 authored by Valentina Gambardella, Jaume Capdevila, Yasutoshi Kuboki, Olatunji B Alese, Daniel Morgensztern, Cyrus Sayehli, Miguel F Sanmamed, Edurne Arriola, Zohra Oum’ Hamed, Eric Song, Matus Studeny

The above is an infographic summary of a clinical trial for patients with small cell lung cancer and other neuroendocrine tumours that are positive for DLL3. Unless otherwise specified, the content for this infographic has undergone a medical, legal, and regulatory (MLR) review and approval process by Boehringer Ingelheim. Content developed with authors.

History

Disclaimer

This study was sponsored by Boehringer Ingelheim. Medical writing support provided by Ashfield MedComms agency and Lynn Pritchard writer. Medical Writing support and open access APCs were funded by Boehringer Ingelheim.

Infographic of: Phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients with DLL3-positive tumours: focus on extrapulmonary neuroendocrine carcinomas

History

Disclaimer

Usage metrics

Categories

Keywords

Licence

Exports